Columvi (Glofitamab-Gxbm) for Lymphoma

Overview
Columvi is approved by the U.S. Food and Drug Administration (FDA) to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBLC) not otherwise specified or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. Columvi is also known by its drug name, glofitamab-gxbm.

Columvi is a bispecific CD20-directed CD3 T-cell engager. It works by binding to  proteins called CD20 and CD3, found respectively on the surfaces of B cells and T cells. This enables a person’s immune system to attack and destroy cancer cells.

How do I take it?
Prescribing information states that Columvi is administered by intravenous IV) infusion. The treatment cycle generally includes a step-up dosing schedule, with initial pretreatment with obinutuzumab (an antibody drug), followed by two step-up doses of Columvi, seven days apart, before reaching the regular treatment dose. The regular treatment dose is usually administered on the first day of each 21-day cycle. Columvi should be taken exactly as prescribed by a health care provider.

Side effects
Common side effects of Columvi include cytokine release syndrome, musculoskeletal pain, rash, fatigue, decreased lymphocyte counts, decreased phosphate levels, decreased neutrophil counts, increased uric acid levels, and decreased fibrinogen.

Rare but serious side effects may include neurologic toxicity, such as immune effector cell-associated neurotoxicity syndrome (ICANS); serious infections, which can be fatal; and tumor flare reactions. Columvi may also cause embryo-fetal toxicity, which can harm an unborn child. 

For more information about this treatment, visit:

Label: Columvi — Glofitamab Concentrate — DailyMed